BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33239431)

  • 1. Nucleoporin 210 Serves a Key Scaffold for SMARCB1 in Liver Cancer.
    Hong SH; Son KH; Ha SY; Wee TI; Choi SK; Won JE; Han HD; Ro Y; Park YM; Eun JW; Nam SW; Han JW; Kang K; You JS
    Cancer Res; 2021 Jan; 81(2):356-370. PubMed ID: 33239431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia.
    Chatterjee SS; Biswas M; Boila LD; Banerjee D; Sengupta A
    Mol Cancer Res; 2018 May; 16(5):791-804. PubMed ID: 29483235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
    Kohashi K; Oda Y
    Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.
    Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
    Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation.
    Wang X; Lee RS; Alver BH; Haswell JR; Wang S; Mieczkowski J; Drier Y; Gillespie SM; Archer TC; Wu JN; Tzvetkov EP; Troisi EC; Pomeroy SL; Biegel JA; Tolstorukov MY; Bernstein BE; Park PJ; Roberts CW
    Nat Genet; 2017 Feb; 49(2):289-295. PubMed ID: 27941797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation.
    Erkek S; Johann PD; Finetti MA; Drosos Y; Chou HC; Zapatka M; Sturm D; Jones DTW; Korshunov A; Rhyzova M; Wolf S; Mallm JP; Beck K; Witt O; Kulozik AE; Frühwald MC; Northcott PA; Korbel JO; Lichter P; Eils R; Gajjar A; Roberts CWM; Williamson D; Hasselblatt M; Chavez L; Pfister SM; Kool M
    Cancer Cell; 2019 Jan; 35(1):95-110.e8. PubMed ID: 30595504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smarcb1 maintains the cellular identity and the chromatin landscapes of mouse embryonic stem cells.
    Sakakura M; Ohta S; Yagi M; Tanaka A; Norihide J; Woltjen K; Yamamoto T; Yamada Y
    Biochem Biophys Res Commun; 2019 Nov; 519(4):705-713. PubMed ID: 31543342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor SMARCB1 suppresses super-enhancers to govern hESC lineage determination.
    Langer LF; Ward JM; Archer TK
    Elife; 2019 Apr; 8():. PubMed ID: 31033435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
    Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
    Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5.
    Li M; Shen Y; Xiong Y; Wang S; Li C; Bai J; Zhang Y
    Cell Prolif; 2021 Dec; 54(12):e13136. PubMed ID: 34668612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MYC by the SMARCB1 tumor suppressor.
    Weissmiller AM; Wang J; Lorey SL; Howard GC; Martinez E; Liu Q; Tansey WP
    Nat Commun; 2019 May; 10(1):2014. PubMed ID: 31043611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
    Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
    Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWI/SNF complex in cancer.
    Lu C; Allis CD
    Nat Genet; 2017 Jan; 49(2):178-179. PubMed ID: 28138149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent SMARCB1 Mutations Reveal a Nucleosome Acidic Patch Interaction Site That Potentiates mSWI/SNF Complex Chromatin Remodeling.
    Valencia AM; Collings CK; Dao HT; St Pierre R; Cheng YC; Huang J; Sun ZY; Seo HS; Mashtalir N; Comstock DE; Bolonduro O; Vangos NE; Yeoh ZC; Dornon MK; Hermawan C; Barrett L; Dhe-Paganon S; Woolf CJ; Muir TW; Kadoch C
    Cell; 2019 Nov; 179(6):1342-1356.e23. PubMed ID: 31759698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
    Jia L; Carlo MI; Khan H; Nanjangud GJ; Rana S; Cimera R; Zhang Y; Hakimi AA; Verma AK; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE; Gartrell BA; Chen YB
    Mod Pathol; 2019 Sep; 32(9):1329-1343. PubMed ID: 30980040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.
    Oike T; Ogiwara H; Nakano T; Yokota J; Kohno T
    Jpn J Clin Oncol; 2013 Sep; 43(9):849-55. PubMed ID: 23904343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
    Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
    PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors.
    Xue Y; Zhu X; Meehan B; Venneti S; Martinez D; Morin G; Maïga RI; Chen H; Papadakis AI; Johnson RM; O'Sullivan MJ; Erdreich-Epstein A; Gotlieb WH; Park M; Judkins AR; Pelletier J; Foulkes WD; Rak J; Huang S
    J Pathol; 2020 Sep; 252(1):77-87. PubMed ID: 32558936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.